Author:
Hu Xueqing,Khatri Ujjwol,Shen Tao,Wu Jie
Publisher
Springer Science and Business Media LLC
Reference76 articles.
1. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014; 14(3): 173–186
2. Thein KZ, Velcheti V, Mooers BHM, Wu J, Subbiah V. Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 2021; 7(12): 1074–1088
3. Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol 2018; 15(3): 151–167
4. Liu X, Hu X, Shen T, Li Q, Mooers BHM, Wu J. RET kinase alterations in targeted cancer therapy. Cancer Drug Resist 2020; 3(3): 472–481
5. Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-art strategies for targeting RET-dependent cancers. J Clin Oncol 2020; 38(11): 1209–1221
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献